Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Child-Pugh A classification.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
Received an immune checkpoint inhibitor in first-line (1L) hepatocellular carcinoma (HCC) treatment regimen.
Adequate hematologic and end-organ function.
Tissue biopsy at screening.
Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies.
You may not be if
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
Prior treatment with an approved tyrosine kinase inhibitor (for example sorafenib or Lenvatinib) in 1L HCC treatment regimen.
History of malignancy other than hepatocellular carcinoma (HCC) within 5 years prior to screening.
Hepatic encephalopathy or requirement for medications to prevent or control encephalopathy.
Moderate or severe ascites requiring recurrent non-pharmacologic intervention to maintain symptomatic control.
Coinfection with active HBV infection and active HCV infection.
Prior history of grade 3 or higher immune-mediated adverse event or discontinuation due to immune-mediated adverse events.
Prior history of recurrent grade 2 or higher interstitial lung disease/pneumonitis.
Clareo Health | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
